Published in Lancet on August 15, 2005
The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet (2009) 9.68
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature (2012) 7.76
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell (2013) 6.47
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS (2010) 3.26
Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood (2008) 3.05
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (2006) 2.86
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol (2012) 2.80
Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation. J Clin Invest (2009) 2.75
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol (2009) 2.47
Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res (2008) 2.40
Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J (2007) 2.37
HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathog (2007) 2.33
CREB-binding protein controls response to cocaine by acetylating histones at the fosB promoter in the mouse striatum. Proc Natl Acad Sci U S A (2005) 2.28
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol (2007) 2.24
Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294. J Biol Chem (2010) 2.23
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J (2007) 2.20
Generation of HIV latency in humanized BLT mice. J Virol (2011) 2.20
Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol (2010) 2.13
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One (2010) 2.09
Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog (2006) 2.08
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res (2009) 2.03
Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS (2011) 2.00
Bryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent manner. PLoS One (2010) 1.95
Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods (2009) 1.91
Prospects for treatment of latent HIV. Clin Pharmacol Ther (2012) 1.91
HIV and the chemokine system: 10 years later. EMBO J (2006) 1.88
Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis (2012) 1.72
HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission. PLoS Pathog (2015) 1.71
An integrated overview of HIV-1 latency. Cell (2013) 1.68
Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses (2009) 1.66
Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol (2011) 1.61
HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology (2007) 1.61
"Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology (2009) 1.59
Determinants of the establishment of human immunodeficiency virus type 1 latency. J Virol (2009) 1.55
Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother (2013) 1.53
Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Regulation of HIV-1 latency by T-cell activation. Cytokine (2007) 1.48
Targeting HIV latency: pharmacologic strategies toward eradication. Drug Discov Today (2012) 1.47
A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients. Virology (2008) 1.45
Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem (2011) 1.45
5' long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. Retrovirology (2006) 1.45
Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol (2010) 1.40
Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins. PLoS Med (2006) 1.38
Curing HIV: Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol (2011) 1.38
Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol (2006) 1.35
Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol (2013) 1.35
Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med (2011) 1.30
HIV reservoirs and latency models. Virology (2011) 1.29
International AIDS Society global scientific strategy: towards an HIV cure 2016. Nat Med (2016) 1.29
Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activation. J Virol (2006) 1.29
Combined approaches for HIV cure. Curr Opin HIV AIDS (2013) 1.23
The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr (2010) 1.22
Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy. PLoS One (2008) 1.21
Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PLoS One (2011) 1.21
Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci U S A (2012) 1.19
Past, present and future: 30 years of HIV research. Nat Rev Microbiol (2013) 1.19
Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation. Proc Natl Acad Sci U S A (2009) 1.19
Finding a cure for HIV: will it ever be achievable? J Int AIDS Soc (2011) 1.18
Histone deacetylases in skeletal development and bone mass maintenance. Gene (2010) 1.16
Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. BMC Infect Dis (2008) 1.15
Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother (2013) 1.12
Activation of latent HIV using drug-loaded nanoparticles. PLoS One (2011) 1.10
Primary cell model for activation-inducible human immunodeficiency virus. J Virol (2007) 1.10
Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure. AIDS (2013) 1.08
Eradication of HIV: current challenges and new directions. J Antimicrob Chemother (2008) 1.08
Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes. J Neuroimmune Pharmacol (2010) 1.08
From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. Bioessays (2013) 1.07
Identification of cellular proteins that maintain retroviral epigenetic silencing: evidence for an antiviral response. J Virol (2007) 1.06
Framing expectations in early HIV cure research. Trends Microbiol (2014) 1.06
Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling. AIDS (2014) 1.05
HIV latency: present knowledge, future directions. Future Virol (2006) 1.04
Chromatin, gene silencing and HIV latency. Genome Biol (2007) 1.01
Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]. PLoS One (2013) 1.01
Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy. Neurol Clin (2008) 1.01
Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation. J Virol (2013) 1.00
Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs. Virology (2011) 0.98
High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor. J Biol Chem (2011) 0.97
Lost in transcription: molecular mechanisms that control HIV latency. Viruses (2013) 0.96
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96
Antiretroviral treatment 2010: progress and controversies. J Acquir Immune Defic Syndr (2010) 0.96
Valproic acid and HIV-1 latency: beyond the sound bite. Retrovirology (2005) 0.96
Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1. J Virol (2012) 0.95
Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother (2012) 0.95
High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. J Virol (2013) 0.94
Human immunodeficiency virus type 1 latency model for high-throughput screening. Antimicrob Agents Chemother (2005) 0.94
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med (1999) 7.07
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (2000) 7.01
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA (1999) 4.98
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol (2000) 4.46
Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med (2000) 4.12
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 4.08
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol (2000) 3.43
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17
Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol (1999) 3.15
Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis (1998) 2.98
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A (2003) 2.95
Molecular characterization, reactivation, and depletion of latent HIV. Immunity (2003) 2.80
Dilution assay statistics. J Clin Microbiol (1994) 2.61
Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol (2002) 2.52
Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol (1999) 2.42
IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART. J Clin Invest (2005) 2.41
Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS (2002) 2.40
Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS (1999) 2.09
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr (2004) 2.05
Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production. J Virol (1994) 1.98
Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis (2002) 1.91
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol (2001) 1.75
Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. J Infect Dis (2004) 1.64
Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis (2001) 1.54
Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF. J Virol (1997) 1.48
Reservoirs, sanctuaries, and residual disease: the hiding spots of HIV-1. HIV Clin Trials (2003) 1.44
Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS (2000) 1.41
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS (2004) 1.28
Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. J Virol (2002) 1.24
Design and analysis of serial limiting dilution assays with small sample sizes. J Immunol Methods (1999) 1.12
Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther (1994) 1.10
Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. AIDS Res Hum Retroviruses (2000) 1.10
Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies. Biochem Pharmacol (2004) 1.08
Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells. J Acquir Immune Defic Syndr (2004) 1.05
Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS (2000) 1.03
Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. Clin Infect Dis (2004) 0.89
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis (2011) 10.96
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
The challenge of finding a cure for HIV infection. Science (2009) 8.41
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol (2005) 7.91
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 7.14
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol (2004) 6.26
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis (2008) 5.20
The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS (2007) 5.18
A methodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol (2008) 5.11
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis (2007) 4.52
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis (2003) 4.51
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol (2007) 4.41
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses (2009) 4.32
Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med (2013) 4.26
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med (2009) 4.22
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis (2005) 3.93
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA (2004) 3.74
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One (2009) 3.66
Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med (2008) 3.66
2011 update of the drug resistance mutations in HIV-1. Top Antivir Med (2011) 3.66
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Recombinant origin of the retrovirus XMRV. Science (2011) 3.54
Highly precise measurement of HIV DNA by droplet digital PCR. PLoS One (2013) 3.53
Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med (2009) 3.52
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J Infect Dis (2012) 3.42
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
HIV-1 viral load assays for resource-limited settings. PLoS Med (2006) 3.30
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 3.24
Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol (2004) 3.20
Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS (2004) 3.17
Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med (2010) 3.14
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe (2010) 3.08
Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med (2006) 3.06
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol (2008) 3.04
Patients with new onset haematuria: assessing the discriminant value of clinical information in relation to urological malignancies. Br J Gen Pract (2002) 3.01
Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS (2003) 2.97
The solitary wave of asexual evolution. Proc Natl Acad Sci U S A (2003) 2.97
Effects of retroviruses on host genome function. Annu Rev Genet (2008) 2.96
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA (2002) 2.96
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91
Endogenous non-retroviral RNA virus elements in mammalian genomes. Nature (2010) 2.91
Update of the Drug Resistance Mutations in HIV-1. Top HIV Med (2008) 2.91
Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med (2010) 2.91
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87